echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Application for clinical acceptance of kabalatin heavy tartrate tablets, a new Alzheimer's drug of Jingxin Pharmaceutical Co., Ltd

    Application for clinical acceptance of kabalatin heavy tartrate tablets, a new Alzheimer's drug of Jingxin Pharmaceutical Co., Ltd

    • Last Update: 2014-12-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the information on the website of the State Food and Drug Administration (CFDA), the application of kabalatin tartrate tablets from Beijing New Pharmaceutical Co., Ltd has been accepted clinically At present, there is no domestic enterprise to approve kabalastine bitartrate tablets, and only one original research and production of capsule According to the public information, carbalatin bitartrate is an acetylcholinesterase inhibitor, which is the mainstream drug for the treatment of Alzheimer's disease The original manufacturer is Novartis The experimental data showed that kabalatin tartrate was well tolerated to mild and moderate Alzheimer's disease due to no metabolism of liver and P450 (cytochrome) It was highly evaluated in a prospective, randomized, multicenter, double-blind study conducted in 45 countries including Europe and the United States According to information on CFDA website, at present, the domestic market of kabalanine bitartrate is monopolized by Novartis In 2008, the amount of drug use in sample hospitals was 4.4 million yuan, up 54% year on year It is worth mentioning that in addition to tablets, Beijing New Pharmaceutical Co., Ltd has applied for the production approval of the drug capsule in 2013, and the domestic enterprises that are developing the product include Huahai Pharmaceutical Co., Ltd and Enhua Pharmaceutical Co., Ltd Beijing New Pharmaceutical Co., Ltd is mainly engaged in fluoroquinolones and preparations for cardiovascular, cerebrovascular and digestive systems, and has completed the transformation from APIs to preparations However, at present, the company's preparation products are relatively single, and the market is optimistic that the company's reserve varieties will successively launch a rich product line.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.